A 844606α7 nAChR partial agonist CAS# 861119-08-6 |
- SB 431542
Catalog No.:BCC3658
CAS No.:301836-41-9
- SB-505124 hydrochloride
Catalog No.:BCC1930
CAS No.:356559-13-2
- SB525334
Catalog No.:BCC2531
CAS No.:356559-20-1
- SD-208
Catalog No.:BCC1938
CAS No.:627536-09-8
- LY2109761
Catalog No.:BCC3806
CAS No.:700874-71-1
- LY2157299
Catalog No.:BCC3709
CAS No.:700874-72-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 861119-08-6 | SDF | Download SDF |
PubChem ID | 11461365 | Appearance | Powder |
Formula | C20H20N2O2 | M.Wt | 320.38 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 5 mM in ethanol with gentle warming | ||
Chemical Name | 2-(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)xanthen-9-one | ||
SMILES | CN1CC2CN(CC2C1)C3=CC4=C(C=C3)OC5=CC=CC=C5C4=O | ||
Standard InChIKey | WUJHMDPPANTBTQ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C20H20N2O2/c1-21-9-13-11-22(12-14(13)10-21)15-6-7-19-17(8-15)20(23)16-4-2-3-5-18(16)24-19/h2-8,13-14H,9-12H2,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective α7 nicotinic acetylcholine receptor (nAChR) partial agonist (EC50 values are 1.4 and 2.2 μM at human and rat receptors respectively). Displays no measurable effect on α4β2 nAChRs. Stimulates α7 nAChR-induced ERK1/2 phosphorylation in PC12 cells. |
A 844606 Dilution Calculator
A 844606 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1213 mL | 15.6065 mL | 31.2129 mL | 62.4259 mL | 78.0323 mL |
5 mM | 0.6243 mL | 3.1213 mL | 6.2426 mL | 12.4852 mL | 15.6065 mL |
10 mM | 0.3121 mL | 1.5606 mL | 3.1213 mL | 6.2426 mL | 7.8032 mL |
50 mM | 0.0624 mL | 0.3121 mL | 0.6243 mL | 1.2485 mL | 1.5606 mL |
100 mM | 0.0312 mL | 0.1561 mL | 0.3121 mL | 0.6243 mL | 0.7803 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- M617
Catalog No.:BCC5929
CAS No.:860790-38-1
- Fmoc-Trp-OPfp
Catalog No.:BCC3557
CAS No.:86069-87-6
- Fmoc-β-Homo-Pro-OH
Catalog No.:BCC2627
CAS No.:86069-86-5
- Fmoc-Glu(OtBu)-OPfp
Catalog No.:BCC3495
CAS No.:86061-04-3
- Fmoc-Asp(OtBu)-OPfp
Catalog No.:BCC3091
CAS No.:86061-01-0
- Fmoc-Gln-OPfp
Catalog No.:BCC3484
CAS No.:86061-00-9
- Fmoc-Asn-OPfp
Catalog No.:BCC3080
CAS No.:86060-99-3
- Fmoc-Lys(Boc)-OPfp
Catalog No.:BCC3517
CAS No.:86060-98-2
- Fmoc-Cys(Acm)-OPfp
Catalog No.:BCC3474
CAS No.:86060-96-0
- Fmoc-Met-OPfp
Catalog No.:BCC3529
CAS No.:86060-94-8
- Fmoc-Tyr(tBu)-OPfp
Catalog No.:BCC3568
CAS No.:86060-93-7
- Fmoc-Phe-OPfp
Catalog No.:BCC3536
CAS No.:86060-92-6
- 5'-Fluoroindirubinoxime
Catalog No.:BCC6104
CAS No.:861214-33-7
- Fmoc-D-Phe-OH
Catalog No.:BCC3537
CAS No.:86123-10-6
- Fmoc-D-Trp-OH
Catalog No.:BCC3559
CAS No.:86123-11-7
- SKF 86466 hydrochloride
Catalog No.:BCC7795
CAS No.:86129-54-6
- A-740003
Catalog No.:BCC1322
CAS No.:861393-28-4
- 2''-O-Beta-L-Galorientin
Catalog No.:BCN3804
CAS No.:861691-37-4
- 7-Methoxy-3,4-dihydro-1-naphthalenylacetonitrile
Catalog No.:BCC8781
CAS No.:861960-34-1
- Anamorelin hydrochloride
Catalog No.:BCC1364
CAS No.:861998-00-7
- Nandrolone undecylate
Catalog No.:BCC9090
CAS No.:862-89-5
- Mirodenafil
Catalog No.:BCC5254
CAS No.:862189-95-5
- Valeriotriate B
Catalog No.:BCN6751
CAS No.:862255-64-9
- RA VII
Catalog No.:BCN3512
CAS No.:86229-97-2
In vivo evaluation of alpha7 nicotinic acetylcholine receptor agonists [11C]A-582941 and [11C]A-844606 in mice and conscious monkeys.[Pubmed:20126539]
PLoS One. 2010 Feb 1;5(2):e8961.
BACKGROUND: The alpha7 nicotinic acetylcholine receptors (nAChRs) play an important role in the pathophysiology of neuropsychiatric diseases such as schizophrenia and Alzheimer's disease. The goal of this study was to evaluate the two carbon-11-labeled alpha7 nAChR agonists [(11)C]A-582941 and [(11)C]A-844606 for their potential as novel positron emission tomography (PET) tracers. METHODOLOGY/PRINCIPAL FINDINGS: The two tracers were synthesized by methylation of the corresponding desmethyl precursors using [(11)C]methyl triflate. Effects of receptor blockade in mice were determined by coinjection of either tracer along with a carrier or an excess amount of a selective alpha7 nAChR agonist (SSR180711). Metabolic stability was investigated using radio-HPLC. Dynamic PET scans were performed in conscious monkeys with/without SSR180711-treatment. [(11)C]A-582941 and [(11)C]A-844606 showed high uptake in the mouse brain. Most radioactive compounds in the brain were detected as an unchanged form. However, regional selectivity and selective receptor blockade were not clearly observed for either compound in the mouse brain. On the other hand, the total distribution volume of [(11)C]A-582941 and [(11)C]A-844606 was high in the hippocampus and thalamus but low in the cerebellum in the conscious monkey brain, and reduced by pretreatment with SSR180711. CONCLUSIONS/SIGNIFICANCE: A nonhuman primate study suggests that [(11)C]A-582941 and [(11)C]A-844606 would be potential PET ligands for imaging alpha7 nAChRs in the human brain.
alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues.[Pubmed:18157163]
Br J Pharmacol. 2008 Mar;153(5):1054-61.
BACKGROUND AND PURPOSE: The alpha7 nicotinic acetylcholine receptor (nAChR) has attracted considerable interest as a target for cognitive enhancement in schizophrenia and Alzheimer's Disease. However, most recently described alpha7 agonists are derived from the quinuclidine structural class. Alternatively, the present study identifies tilorone as a novel alpha7-selective agonist and characterizes analogues developed from this lead. EXPERIMENTAL APPROACH: Activity and selectivity were determined from rat brain alpha7 and alpha4beta2 nAChR binding, recombinant nAChR activation, and native alpha7 nAChR mediated stimulation of ERK1/2 phosphorylation in PC12 cells. KEY RESULTS: Tilorone bound alpha7 nAChR (IC(50) 110 nM) with high selectivity relative to alpha4beta2 (IC(50) 70 000 nM), activated human alpha7 nAChR with an EC(50) value of 2.5 microM and maximal response of 67% relative to acetylcholine, and showed little agonist effect at human alpha3beta4 or alpha4beta2 nAChRs. However, the rat alpha7 nAChR maximal response was only 34%. Lead optimization led to 2-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-xanthen-9-one (A-844606) with improved binding (alpha7 IC(50) 11 nM, alpha4beta2 IC(50)>30 000 nM) and activity at both human and rat alpha7 nAChR (EC(50)s 1.4 and 2.2 microM and apparent efficacies 61 and 63%, respectively). These compounds also activated native alpha7 nAChR, stimulating ERK1/2 phosphorylation in PC12 cells. CONCLUSIONS AND IMPLICATIONS: Tilorone, known as an interferon inducer, is a selective alpha7 nAChR agonist, suggesting utility of the fluorenone pharmacophore for the development of alpha7 nAChR selective agonists. Whether alpha7 stimulation mediates interferon induction, or whether interferon induction may influence the potential anti-inflammatory properties of alpha7 nAChR agonists remains to be elucidated.